{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T20:14:50Z","timestamp":1768076090296,"version":"3.49.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.drudis.2021.06.019","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T04:28:02Z","timestamp":1627446482000},"page":"2608-2618","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Ebola outbreaks: A stress test of the preparedness of medicines regulatory systems for public health crises"],"prefix":"10.1016","volume":"26","author":[{"given":"Rafael","family":"Amaral","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5542-9993","authenticated-orcid":false,"given":"Carla","family":"Torre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2761-0955","authenticated-orcid":false,"given":"Bruno","family":"Sepodes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.drudis.2021.06.019_b0005","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMp1813905","article-title":"Politics and pandemics","volume":"379","author":"Klain","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2021.06.019_b0010","unstructured":"WHO. Ebola virus disease. www.who.int\/en\/news-room\/fact-sheets\/detail\/ebola-virus-disease. Updated February 23, 2021 Accessed June 14, 2021."},{"key":"10.1016\/j.drudis.2021.06.019_b0015","unstructured":"CDC. What is Ebola virus disease? www.cdc.gov\/vhf\/ebola\/about.html. Updated April 27, 2021. Accessed June 14, 2021."},{"key":"10.1016\/j.drudis.2021.06.019_b0020","unstructured":"CDC. Signs and symptoms. www.cdc.gov\/vhf\/ebola\/symptoms\/index.html. Updated May 4, 2021. Accessed June 14, 2021."},{"key":"10.1016\/j.drudis.2021.06.019_b0025","unstructured":"CDC. History of Ebola virus disease (EVD) outbreaks. www.cdc.gov\/vhf\/ebola\/history\/chronology.html. Updated May 3, 2021. Accessed June 14, 2021."},{"key":"10.1016\/j.drudis.2021.06.019_b0030","unstructured":"WHO. Statement on the 1st meeting of the IHR Emergency Committee on the 2014 Ebola outbreak in West Africa. www.who.int\/mediacentre\/news\/statements\/2014\/ebola-20140808\/en\/. Published August 8, 2014. Accessed June 14, 2021."},{"key":"10.1016\/j.drudis.2021.06.019_b0035","unstructured":"WHO. Ebola outbreak in the Democratic Republic of the Congo declared a Public Health Emergency of International Concern. www.who.int\/news\/item\/17-07-2019-ebola-outbreak-in-the-democratic-republic-of-the-congo-declared-a-public-health-emergency-of-international-concern. Published July 17, 2019. Accessed June 14, 2021."},{"issue":"3","key":"10.1016\/j.drudis.2021.06.019_b0040","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/jlb\/lsw046","article-title":"EBOLA and FDA: reviewing the response to the 2014 outbreak, to find lessons for the future","volume":"3","author":"Largent","year":"2016","journal-title":"J Law Biosci"},{"key":"10.1016\/j.drudis.2021.06.019_b0045","doi-asserted-by":"crossref","unstructured":"Keusch G, McAdam K, Cuff PA, Mancher M, Busta ER, eds. Integrating Clinical Research into Epidemic Response: The Ebola Experience. Washington, DC: The National Academies Press; 2017.","DOI":"10.17226\/24739"},{"key":"10.1016\/j.drudis.2021.06.019_b0050","unstructured":"EMA. Ebola. www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/ebola. Accessed June 14, 2021."},{"key":"10.1016\/j.drudis.2021.06.019_b0055","unstructured":"EMA. EMA advises on development plan for GSK Ebola vaccine. www.ema.europa.eu\/en\/news\/ema-advises-development-plan-gsk-ebola-vaccine. Published October 29, 2014. Accessed June 14, 2021."},{"key":"10.1016\/j.drudis.2021.06.019_b0060","unstructured":"EMA. Orphan designation: overview. www.ema.europa.eu\/en\/human-regulatory\/overview\/orphan-designation-overview. Accessed June 14, 2021."},{"key":"10.1016\/j.drudis.2021.06.019_b0065","unstructured":"EMA. PRIME: priority medicines. www.ema.europa.eu\/en\/human-regulatory\/research-development\/prime-priority-medicines. Accessed June 14, 2021."},{"key":"10.1016\/j.drudis.2021.06.019_b0070","unstructured":"Committee for Medicinal Products for Human Use. CHMP assessment report: medicinal products under development for the treatment of Ebola. London: EMA; 2016"},{"key":"10.1016\/j.drudis.2021.06.019_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1002191","article-title":"What is the purpose of the Orphan Drug Act?","volume":"14","author":"Herder","year":"2017","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.drudis.2021.06.019_b0080","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1089\/blr.2015.9999","article-title":"FDA\u2019s expedited approval mechanisms for new drug products","volume":"34","author":"Kepplinger","year":"2015","journal-title":"Biotechnol Law Rep"},{"issue":"9","key":"10.1016\/j.drudis.2021.06.019_b0085","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/j.clinthera.2015.07.011","article-title":"Expedited programs for serious conditions: an update on breakthrough therapy designation","volume":"37","author":"Kwok","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.drudis.2021.06.019_b0090","unstructured":"FDA. Emergency use authorization. www.fda.gov\/emergency-preparedness-and-response\/mcm-legal-regulatory-and-policy-framework\/emergency-use-authorization#ebola. Updated May 11, 2021. Accessed June 14, 2021."},{"key":"10.1016\/j.drudis.2021.06.019_b0095","unstructured":"United States Congress. S.2917 - Adding Ebola to the FDA Priority Review Voucher Program Act. www.congress.gov\/bill\/113th-congress\/senate-bill\/2917\/text. Published December 16, 2014. Accessed June 14, 2021."},{"key":"10.1016\/j.drudis.2021.06.019_b0100","series-title":"Emergency use listing procedure","author":"WHO","year":"2020"},{"key":"10.1016\/j.drudis.2021.06.019_b0105","series-title":"Meeting report: WHO informal consultation on options to improve regulatory preparedness to address public health emergencies","author":"Griffiths","year":"2017"},{"key":"10.1016\/j.drudis.2021.06.019_b0110","series-title":"Meeting summary of the WHO consultation on potential Ebola therapies and vaccines","author":"WHO","year":"2014"},{"issue":"SI1","key":"10.1016\/j.drudis.2021.06.019_b0115","doi-asserted-by":"crossref","first-page":"75","DOI":"10.29245\/2578-3009\/2018\/si.1111","article-title":"The role of the African Vaccine Regulatory Forum (AVAREF) in the accelerated clinical evaluation of Ebola vaccine candidates during the large West Africa epidemic","volume":"2","author":"Akanmori","year":"2018","journal-title":"J Immunol Sci"},{"key":"10.1016\/j.drudis.2021.06.019_b0120","unstructured":"WHO. Roadmap for introduction and roll\u2010out of Merck rVSV\u2010ZEBOV Ebola Virus Disease vaccine in African countries - revised working paper following AVAREF meeting February 2019. Geneva: WHO; 2019."},{"key":"10.1016\/j.drudis.2021.06.019_b0125","series-title":"Public Report: Ebola R&D Landscape of clinical candidates and trials","author":"WHO","year":"2015"},{"key":"10.1016\/j.drudis.2021.06.019_b0130","unstructured":"WHO. Ebola vaccines, therapies, and diagnostics. www.who.int\/medicines\/emp_ebola_q_as\/en\/. Updated November 21, 2015. Accessed June 14, 2021."},{"issue":"11","key":"10.1016\/j.drudis.2021.06.019_b0135","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMp1508708","article-title":"Combating emerging threats \u2014 accelerating the availability of medical therapies","volume":"373","author":"Borio","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2021.06.019_b0140","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","article-title":"A randomized, controlled trial of ZMapp for Ebola virus infection","volume":"375","author":"The PREVAIL II Writing Group","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2021.06.019_b0145","series-title":"Guidance for managing ethical issues in infectious disease outbreaks","author":"WHO","year":"2016"},{"key":"10.1016\/j.drudis.2021.06.019_b0150","doi-asserted-by":"crossref","unstructured":"Higgs ES, Dubey SA, Coller BAG, Simon JK, Bollinger L, Sorenson RA, et al. Accelerating vaccine development during the 2013\u20132016 West African Ebola virus disease outbreak. In: M\u00fchlberger E, Hensley LL, Towner JS, eds. Marburg- and Ebolaviruses: From Ecosystems to Molecules. London: Springer; 2017: 229\u2013261.","DOI":"10.1007\/82_2017_53"},{"issue":"10","key":"10.1016\/j.drudis.2021.06.019_b0155","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/14760584.2018.1527692","article-title":"Unprecedented pace and partnerships: the story of and lessons learned from one Ebola vaccine program","volume":"17","author":"Gupta","year":"2018","journal-title":"Expert Rev Vaccines"},{"issue":"10068","key":"10.1016\/j.drudis.2021.06.019_b0160","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.drudis.2021.06.019_b0165","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S1473-3099(17)30541-8","article-title":"Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report","volume":"17","author":"Gsell","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.drudis.2021.06.019_b0170","unstructured":"IMI. Ebola+. www.imi.europa.eu\/projects-results\/project-factsheets\/ebola. Accessed June 14, 2021."},{"issue":"9","key":"10.1016\/j.drudis.2021.06.019_b0175","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1080\/14760584.2016.1187566","article-title":"Ebola virus disease candidate vaccines under evaluation in clinical trials","volume":"15","author":"Martins","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.drudis.2021.06.019_b0180","series-title":"Summary of the April 2017 meeting of the Strategic Advisory Group of Experts on Immunization","author":"WHO Strategic Advisory Group of Experts","year":"2017"},{"key":"10.1016\/j.drudis.2021.06.019_b0185","unstructured":"WHO. Ebola vaccination begins in North Kivu. www.who.int\/news\/item\/08-08-2018-ebola-vaccination-begins-in-north-kivu. Published August 8, 2018. Accessed June 14, 2021."},{"key":"10.1016\/j.drudis.2021.06.019_b0190","series-title":"Preliminary results on the efficacy of rVSV-ZEBOV-GP Ebola vaccine using the ring vaccination strategy in the control of an Ebola outbreak in the Democratic Republic of the Congo: an example of integration of research into epidemic response","author":"WHO","year":"2019"},{"key":"10.1016\/j.drudis.2021.06.019_b0195","unstructured":"WHO. Second Ebola vaccine to complement \u2018ring vaccination\u2019 given green light in DRC. www.who.int\/news\/item\/23-09-2019-second-ebola-vaccine-to-complement-ring-vaccination-given-green-light-in-drc. Published September 23, 2019. Accessed June 14, 2021."},{"issue":"21","key":"10.1016\/j.drudis.2021.06.019_b0200","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMp1811751","article-title":"New tools in the Ebola arsenal","volume":"379","author":"Damon","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2021.06.019_b0205","unstructured":"WHO. Ebola treatments approved for compassionate use in current outbreak. www.who.int\/ebola\/drc-2018\/treatments-approved-for-compassionate-use\/en\/. Published June 6, 2018. Accessed June 14, 2021."},{"key":"10.1016\/j.drudis.2021.06.019_b0210","unstructured":"WHO. Democratic Republic of the Congo begins first-ever multi-drug Ebola trial. www.who.int\/news\/item\/26-11-2018-democratic-republic-of-the-congo-begins-first-ever-multi-drug-ebola-trial. Published November 26, 2018. Accessed June 14, 2021."},{"issue":"24","key":"10.1016\/j.drudis.2021.06.019_b0215","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2021.06.019_b0220","series-title":"Assessment report: Ervebo","author":"CHMP","year":"2019"},{"key":"10.1016\/j.drudis.2021.06.019_b0225","unstructured":"FDA. First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response. www.fda.gov\/news-events\/press-announcements\/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking-critical-milestone-public-health.; Published December 19, 2019. Accessed June 14, 2021."},{"issue":"1","key":"10.1016\/j.drudis.2021.06.019_b0230","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-020-0204-7","article-title":"Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens","volume":"5","author":"Wolf","year":"2020","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.drudis.2021.06.019_b0235","unstructured":"EMA. Accelerated assessment. www.ema.europa.eu\/en\/human-regulatory\/marketing-authorisation\/accelerated-assessment. Accessed June 14, 2021."},{"key":"10.1016\/j.drudis.2021.06.019_b0240","unstructured":"EMA. First vaccine to protect against Ebola. www.ema.europa.eu\/en\/news\/first-vaccine-protect-against-ebola. Published October 18, 2019. Accessed June 14, 2021."},{"key":"10.1016\/j.drudis.2021.06.019_b0245","unstructured":"EMA. Conditional marketing authorisation. www.ema.europa.eu\/en\/human-regulatory\/marketing-authorisation\/conditional-marketing-authorisation. Accessed June 14, 2021."},{"key":"10.1016\/j.drudis.2021.06.019_b0250","series-title":"Ervebo - Procedural steps taken and scientific information after the authorisation","author":"EMA","year":"2021"},{"key":"10.1016\/j.drudis.2021.06.019_b0255","unstructured":"WHO. Major milestone for WHO-supported Ebola vaccine. www.who.int\/news\/item\/18-10-2019-major-milestone-for-who-supported-ebola-vaccine. Published October 18, 2019. Accessed June 14, 2021."},{"key":"10.1016\/j.drudis.2021.06.019_b0260","unstructured":"WHO. WHO prequalifies Ebola vaccine, paving the way for its use in high-risk countries. www.who.int\/news-room\/detail\/12-11-2019-who-prequalifies-ebola-vaccine-paving-the-way-for-its-use-in-high-risk-countries. Published November 12, 2019. Accessed June 14, 2021."},{"key":"10.1016\/j.drudis.2021.06.019_b0265","series-title":"Summary basis for regulatory action \u2013 Ervebo","author":"FDA","year":"2019"},{"key":"10.1016\/j.drudis.2021.06.019_b0270","series-title":"Approval letter \u2013 Ervebo","author":"FDA","year":"2019"},{"key":"10.1016\/j.drudis.2021.06.019_b0275","unstructured":"WHO. Four countries in the African region license vaccine in milestone for Ebola prevention. www.who.int\/news-room\/detail\/14-02-2020-four-countries-in-the-african-region-license-vaccine-in-milestone-for-ebola-prevention. Published February 14, 2020. Accessed June 14, 2021."},{"key":"10.1016\/j.drudis.2021.06.019_b0280","series-title":"Assessment report: Zabdeno","author":"CHMP","year":"2020"},{"key":"10.1016\/j.drudis.2021.06.019_b0285","series-title":"Assessment report: Mvabea","author":"CHMP","year":"2020"},{"key":"10.1016\/j.drudis.2021.06.019_b0290","unstructured":"EC. Vaccine against Ebola: Commission grants new market authorisations. https:\/\/ec.europa.eu\/commission\/presscorner\/detail\/en\/IP_20_1248. Published July 1, 2020. Accessed June 14, 2021."},{"key":"10.1016\/j.drudis.2021.06.019_b0295","unstructured":"FDA. FDA approves first treatment for Ebola virus. www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-ebola-virus. Updated October 14, 2020. Accessed June 14, 2021."},{"key":"10.1016\/j.drudis.2021.06.019_b0300","unstructured":"FDA. FDA approves treatment for Ebola virus. www.fda.gov\/drugs\/drug-safety-and-availability\/fda-approves-treatment-ebola-virus?utm_medium=email&utm_source=govdelivery. Updated December 21, 2020. Accessed June 14, 2021."},{"key":"10.1016\/j.drudis.2021.06.019_b0305","series-title":"Approval letter \u2013 Inmazeb","author":"CDER","year":"2020"},{"key":"10.1016\/j.drudis.2021.06.019_b0310","series-title":"Approval letter \u2013 Ebanga","author":"CDER","year":"2020"},{"issue":"10009","key":"10.1016\/j.drudis.2021.06.019_b0315","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/S0140-6736(15)00946-0","article-title":"Will Ebola change the game? Ten essential reforms before the next pandemic. The report of the Harvard-LSHTM Independent Panel on the Global Response to Ebola","volume":"386","author":"Moon","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.drudis.2021.06.019_b0320","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMp1613577","article-title":"New vaccines against epidemic infectious diseases","volume":"376","author":"R\u00f8ttingen","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2021.06.019_b0325","series-title":"WHO Ebola Research and Development Summit - meeting report","author":"WHO","year":"2015"},{"issue":"15","key":"10.1016\/j.drudis.2021.06.019_b0330","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1056\/NEJMp1502918","article-title":"The next epidemic \u2014 lessons from Ebola","volume":"372","author":"Gates","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2021.06.019_b0335","series-title":"Report of the Ebola Interim Assessment Panel","author":"Stocking","year":"2015"},{"key":"10.1016\/j.drudis.2021.06.019_b0340","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1080\/21645515.2018.1442161","article-title":"Lessons learned from Ebola Vaccine R&D during a public health emergency","volume":"14","author":"Kieny","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.drudis.2021.06.019_b0345","unstructured":"WHO. Accelerating R&D processes. www.who.int\/activities\/accelerating-r-d-processes. Accessed June 14, 2021."},{"key":"10.1016\/j.drudis.2021.06.019_b0350","unstructured":"WHO. An R&D blueprint for action to prevent epidemics: funding & coordination models for preparedness and response. Geneva: WHO; 2016."},{"key":"10.1016\/j.drudis.2021.06.019_b0355","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/21645515.2017.1264755","article-title":"EBOVAC1 consortium. A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks","volume":"13","author":"Shukarev","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.drudis.2021.06.019_b0360","unstructured":"FDA. Priority review. www.fda.gov\/patients\/fast-track-breakthrough-therapy-accelerated-approval-priority-review\/priority-review. Updated January 4, 2018. Accessed June 14, 2021."},{"key":"10.1016\/j.drudis.2021.06.019_b0365","unstructured":"WHO. Welcome to medicines prequalification. https:\/\/extranet.who.int\/pqweb\/medicines. Accessed June 14, 2021."},{"key":"10.1016\/j.drudis.2021.06.019_b0370","series-title":"EMA plan for emerging health threats","author":"EMA","year":"2018"},{"key":"10.1016\/j.drudis.2021.06.019_b0375","unstructured":"Office of Emergency Management. FDA Emergency Operations Plan \u2013 Version 3.0. Silver Spring: FDA; 2019."},{"key":"10.1016\/j.drudis.2021.06.019_b0380","unstructured":"EMA. EMA regulatory science to 2025: strategic reflection. Amsterdam: EMA; 2020."},{"key":"10.1016\/j.drudis.2021.06.019_b0385","unstructured":"IMI. Latest COVID-19 vaccine based on technology tested for safety & immunogenicity in IMI Ebola projects. www.imi.europa.eu\/news-events\/newsroom\/latest-covid-19-vaccine-based-technology-tested-safety-immunogenicity-imi. Published March 11, 2021. Accessed June 14, 2021."},{"key":"10.1016\/j.drudis.2021.06.019_b0390","first-page":"296","article-title":"Public health decisions in the COVID-19 pandemic require more than \u2018follow the science\u2019","volume":"47","author":"de Campos-Rudinsky","year":"2021","journal-title":"J Med Ethics"},{"key":"10.1016\/j.drudis.2021.06.019_b0395","unstructured":"CDC. 2014 Ebola outbreak in West Africa epidemic curves. www.cdc.gov\/vhf\/ebola\/history\/2014-2016-outbreak\/cumulative-cases-graphs.html. Updated April 3, 2019. Accessed June 14, 2021."},{"key":"10.1016\/j.drudis.2021.06.019_b0400","unstructured":"WHO. Ebola situation reports: Democratic Republic of the Congo (Archive). www.who.int\/ebola\/situation-reports\/drc-2018\/en\/. Accessed June 14, 2021."},{"key":"10.1016\/j.drudis.2021.06.019_b0405","unstructured":"WHO. Latest numbers as of 21 June 2020. www.afro.who.int\/health-topics\/ebola-virus-disease\/situation-reports. Updated June 21, 2020. Accessed June 14, 2021."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644621003299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644621003299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:53:25Z","timestamp":1761224005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644621003299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":81,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S1359644621003299"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2021.06.019","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ebola outbreaks: A stress test of the preparedness of medicines regulatory systems for public health crises","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2021.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}